Bristol-Myers Squibb May Be Fast-Tracking Its Promising Cancer Drug

03-07-2014 Seeking AlphaComments (0)

Bristol-Myers Squibb

Bristol-Myers Squibb (BMY) appears to be fast-tracking the development of its breakthrough immuno-oncology drug, Nivolumab. The Phase 3 clinical trials were earlier expected to run into the second half of 2015. However, with the recent release of promising data and the early termination of the first batch of Phase 3 trials, the drug may hit the market sooner than expected. Immuno-oncology is a promising area of drug development, and has attracted research funding from several big companies. For Bristol-Myers Squibb, the pipeline seems strong, but Nivolumab remains its most promising drug. The company also collaborated with CytomX Therapeutics recently to develop more immuno-oncology drugs. It agreed to make an upfront payment of $50 million, fund the research and make additional payments of up to $298 million on achieving key milestones. That's not a lot, considering the potential reward from making a breakthrough in this multi-billion dollar market

Read more on Seeking Alpha

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top